Vineet Laboratories Ltd. (IN:VINEETLAB)
:VINEETLAB
Want to see IN:VINEETLAB full AI Analyst Report?
Top Page
Vineet Laboratories Ltd.
(VINEETLAB)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹38.00
▼(-6.20% Downside)
Action:Reiterated
Date:04/28/26
The score is held back primarily by weak financial performance—declining revenue, negative profitability, leverage risk, and uneven cash generation. Technicals are supportive of a recent uptrend but look overbought, while valuation (low P/E) provides some offset.
Positive Factors
Recent Positive Free Cash Flow
A return to positive free cash flow in the latest year indicates the company can generate operating cash after investments, reducing dependence on external funding. Sustained FCF supports debt servicing, working-capital needs and potential reinvestment over the next 2–6 months.
Negative Factors
Steep Revenue Decline
A roughly 44% decline in revenue reflects severe demand or market-share pressures and undermines scale economics. Over several months this compresses margins, reduces cash generation potential, and makes recovery harder without clear demand-restoration initiatives or new revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Recent Positive Free Cash Flow
A return to positive free cash flow in the latest year indicates the company can generate operating cash after investments, reducing dependence on external funding. Sustained FCF supports debt servicing, working-capital needs and potential reinvestment over the next 2–6 months.
Read all positive factors
Vineet Laboratories Ltd. (VINEETLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹662.62M
Dividend YieldN/A
Average Volume (3M)6.84K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth-44.28%
EPS Growth-28.87%
CountryIN
Employees79
SectorHealthcare
Sector Strength45
IndustryChemicals
Share Statistics
EPS (TTM)-18.11
Shares Outstanding19,206,266
10 Day Avg. Volume3,453
30 Day Avg. Volume6,845
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.81
Price to Sales (P/S)0.35
P/FCF Ratio2.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vineet Laboratories Ltd. Business Overview & Revenue Model
Company Description
Vineet Laboratories Ltd. (VINEETLAB) is a leading player in the pharmaceutical and biotechnology sectors, specializing in the development, manufacturing, and distribution of high-quality therapeutic solutions. The company focuses on a diverse rang...
How the Company Makes Money
null...
Vineet Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 570.37M | 749.95M | 1.51B | 2.12B | 1.91B | 2.43B |
| Gross Profit | 73.32M | -124.68M | 139.85M | 399.65M | 454.26M | 306.82M |
| EBITDA | -102.79M | -142.96M | 67.32M | 77.83M | 134.47M | 85.32M |
| Net Income | -166.97M | -201.91M | 10.27M | 12.53M | 66.39M | 17.80M |
Balance Sheet | ||||||
| Total Assets | 906.45M | 945.40M | 1.17B | 1.16B | 1.34B | 1.09B |
| Cash, Cash Equivalents and Short-Term Investments | 6.54M | 6.69M | 2.28M | 6.31M | 181.17M | 21.02M |
| Total Debt | 427.81M | 400.47M | 443.00M | 310.89M | 307.04M | 184.07M |
| Total Liabilities | 764.24M | 798.92M | 821.48M | 821.66M | 1.00B | 821.26M |
| Stockholders Equity | 142.21M | 146.48M | 347.24M | 336.83M | 332.18M | 266.15M |
Cash Flow | ||||||
| Free Cash Flow | 771.00K | 104.46M | -116.61M | -172.50M | 77.15M | -87.12M |
| Operating Cash Flow | 771.00K | 114.91M | -114.27M | -96.16M | 77.15M | -87.12M |
| Investing Cash Flow | -371.00K | -31.82M | -22.22M | -66.86M | -35.72M | -78.05M |
| Financing Cash Flow | -651.00K | -82.30M | 84.30M | 2.73M | 119.55M | 186.15M |
Vineet Laboratories Ltd. Technical Analysis
Positive
40.51
Price Trends
34.72
Negative
33.28
Positive
33.49
Positive
Market Momentum
-0.34
Positive
47.32
Neutral
30.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VINEETLAB, the sentiment is Positive. The current price of 40.51 is above the 20-day moving average (MA) of 35.33, above the 50-day MA of 34.72, and above the 200-day MA of 33.49, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 47.32 is Neutral, neither overbought nor oversold. The STOCH value of 30.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VINEETLAB.
Vineet Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹6.39B | 41.27 | ― | ― | 1.10% | 395.39% | |
65 Neutral | ₹9.55B | 12.44 | ― | 0.38% | 7.53% | 36.87% | |
62 Neutral | ₹6.19B | 22.68 | ― | 0.97% | 34.84% | 26.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹662.62M | -3.16 | ― | ― | -44.28% | -28.87% | |
49 Neutral | ₹1.58B | -22.61 | ― | ― | -27.59% | -676.68% | |
42 Neutral | ₹2.40B | -19.53 | ― | 0.38% | -46.16% | -565.67% |
* Healthcare Sector Average
IN:VINEETLAB
Vineet Laboratories Ltd.
34.50
8.44
32.39%
IN:DIAMINESQ
Diamines & Chemicals Ltd.
245.60
-124.28
-33.60%
IN:DMCC
DMCC Speciality Chemicals Limited
248.15
-20.04
-7.47%
IN:INDOAMIN
Indo Amines Limited
131.50
-27.09
-17.08%
IN:PRIMO
Primo Chemicals Limited
26.36
0.74
2.89%
IN:ISHANCH
Ishan Dyes and Chemicals Limited
60.26
20.80
52.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.